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Background. The importance of 25-hydroxyvitamin D
(25-OHD) serum levels in hemodialysis chronic renal failure
has not been so far histologically evaluated. Information still
lacking relate to the effect of 25-OHD deficiency on serum
parathyroid hormone (PTH) levels and on bone and its rela-
tionship with calcitriol levels.
Methods. This retrospective study has been performed on
a cohort of 104 patients on hemodialysis from more than
12 months, subjected to transiliac bone biopsy for histologic,
histomorphometric, and histodynamic evaluation. The patients,
61 males and 43 females, mean age 52.9 ± 11.7 years, hemodial-
ysis length 97.4 ± 61.4 months, were treated with standard
hemodialysis and did not receive any vitamin D supplementa-
tion. Treatment with calcitriol was not underway at the time of
the biopsy. Transiliac bone biopsies were performed after dou-
ble tetracycline labels. In addition, serum intact PTH (iPTH),
alkaline phosphatase, and 25-OHD were measured. Calcitriol
serum levels was also measured in a subset of patients (N = 53).
The patients were divided according to serum 25-OHD levels in
three groups: (1) 0 to 15 (15 patients), (2) 15 to 30 (38 patients),
and (3) >30 ng/mL (51 patients).
Results. There was no significant difference in average age,
hemodialysis age, serum PTH [490 ± 494, 670 ± 627, and 489 ±
436 pg/mL, respectively (mean ± SD)], alkaline phosphatase,
and calcitriol between the three groups. The parameters double-
labeled surface, trabecular mineralizing surface, and bone for-
mation rate were significantly lower in group 1 than in the other
groups (P < 0.03, < 0.03, and < 0.02, respectively). Osteoblast
surface and adjusted apposition rate were borderline signifi-
cantly lower in group 1 (P < 0.06 and < 0.10). There was no
statistical difference in the biochemical and bone parameters
between groups 2 and 3. A positive significant correlation was
found between several bone static and dynamic parameters and
25-OHD levels in the range 0 to 30 ng/mL, showing a vitamin D
dependence of bone turnover at these serum levels. However,
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actual evidence of an effect on bone of 25-OHD deficiency was
found at serum levels below 20 ng/mL. With increasing 25-OHD
levels beyond 40 ng/mL, a downslope of parameters of bone
turnover was also observed.
Conclusion. Since PTH serum levels are equally elevated in
low and high 25-OHD patients, while calcitriol levels are con-
stantly low, an effect of 25-OHD deficiency (group 1) on bone,
consisting of a mineralization and bone formation defect, can
be hypothesized. The effect of vitamin D deficiency or bone
turnover is found below 20 ng/mL. The optimal level of 25-
OHD appears to be in the order of 20 to 40 ng/mL. Levels of
the D metabolite higher than 40 ng/mL are accompanied by a
reduction of bone turnover.
Serum levels of 25-hydroxyvitamin D (25-OHD) pro-
vide an evaluation of body stores of the vitamin, since
hepatic 25-hydroxylation of cholecalciferol is poorly reg-
ulated and depends on the availability of the substrate.
Low levels of serum 25-OHD are a frequent finding in
the general population [1–3], with special regard to el-
derly or disabled or chronically ill people, unsufficiently
exposed to sun and ultraviolet light, or affected by mal-
nutrition. Serum 25-OHD levels are decreased to insuf-
ficiency mainly during winter and early spring periods
[4, 5]. It is also known that patients with chronic renal
failure have levels of 25-OHD lower than normal with a
progressive decrease in the serum with decreasing renal
function [6, 7]. The deficiency of 25-OHD is associated
to osteomalacia in subjects with normal renal function,
and is a cofactor of impaired mineralization and osteo-
malacia in renal patients [8, 9]. However, the state of
25-OHD deficiency and insufficiency, with special regard
to chronic renal failure, has not been clearly defined.
While in nonrenal patients vitamin D insufficiency is con-
sidered to be present at the serum levels associated with
curtailed calcitriol synthesis, in chronic renal failure, cal-
citriol production is hampered even at relatively elevated
25-OHD levels. The role and extent of extrarenal cal-
citriol synthesis in uremic patients and its contribution to
vitamin D effect on target organs is not known. In addi-
tion, we do not know whether this metabolite of vitamin
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D plays a direct and specific role on bone metabolism
and on parathyroid secretion, independent of calcitriol
serum levels, notoriously low in chronic renal failure. In
facts, we are accustomed to believe that all the vitamin D
activity is exhibited by calcitriol, the vitamin D metabo-
lite which we commonly utilize when it is necessary to
administer vitamin D in chronic renal failure. An inde-
pendent biologic activity of 25-OHD is still a matter of
doubt. It is not known which are the appropriate and
desirable 25-OHD serum levels, in chronic renal failure,
which would avoid adverse consequences on bone and
on parathyroid hormone (PTH) secretion. Most of our
knowledge derives from the study of subjects with nor-
mal renal function and, in the definition of optimal serum
25-OHD levels, reference is usually made to the vitamin
D serum levels which are unable to induce secondary hy-
perparathyroidism [3, 5]. However, in chronic renal fail-
ure, there are many factors of secondary hyperparathy-
roidism, so that an increased secretion of the hormone
due to vitamin D deficiency or insufficiency cannot be
clearly demonstrated. In addition, while it is known that
elderly subjects with normal renal function and low 25-
OHD levels have more frequent hip fractures [10, 11],
increased incidence of fractures are known to be present
in patients on hemodialysis [12, 13] independently of age
and vitamin D status of the patients. Deficiency of 25-
OHD in chronic renal failure appears to be only one and
probably not very decisive factor of bone fractures.
Therefore, a better understanding of the specific role
of 25-OHD deficiency in chronic renal failure should be
obtained from a large study based on bone biopsies with
histologic, histomorphometric, and histodynamic evalua-
tion. Data of this kind are not yet available in the medical
literature. This study compares cross-sectionally patients
with different levels of serum 25-OHD from biochemical
and histologic point of view providing new data on the
effect of low levels of the vitamin D metabolite on bone
static and dynamic parameters.
METHODS
This study has been performed retrospectively on a
cohort of 104 patients on hemodialysis for more than
12 months, with a wide range of PTH serum levels, who
volunteered to undergo a bone biopsy for histologic,
histomorphometric, and histodynamic evaluation. The
patients, 61 males and 43 females, had a mean age of
52.9 ± 11.7 years, and a mean dialytic length of 97.4 ±
61.4 months. The causes of terminal renal failure were
the following: chronic glomerulonephritis in 36 patients,
tubulointerstitial nephropathy in 24 patients, hyperten-
sive/ischemic nephropathy in 16 patients, polycystic kid-
ney disease in 12 patients, diabetic nephropathy in four
patients, renal stone disease and obstructive nephropathy
in two patients, and unknown in ten patients. They did not
receive any cholecalciferol or 25-OHD supplementation.
Most of the patients had been treated previously with rel-
atively limited doses of calcitriol administered orally or
intravenously (1.5 to 3.5 lg/week), but had discontinued
this treatment at least 3 months before bone biopsy in two
patients and more than 5 months in the other patients.
The patients did not receive corticosteroids, nons-
teroidal anti-inflammatory drugs (NSAIDs), anticoagu-
lants, antiepileptics, estrogens, and androgens, at least
since they were on hemodialysis. Phosphate binders were
mainly calcium salts and sevelamer. In the majority of
the patients, regular erythropoietin intravenous treat-
ment was underway. All the patients were treated with
standard hemodialysis, 12 hours a week, divided in three
sessions.
The patients were subjected to transiliac bone biopsy
with a Bordier trocar, following a double-labeling course
with tetracycline per mouth, with a 12-day interval pe-
riod. The biopsy was performed 3 to 5 days after the end
of tetracycline administration. At the same time, a blood
sample was drawn for the following assays: calcium, phos-
phate, 25-hydroxycholecalciferol, intact PTH (iPTH), os-
teocalcin, total alkaline phosphatase, serum C-terminal
cross-linked telopeptide of collagen type I (ICTP), and
1,25-dihydroxycholecalciferol.
Serum 25-hydroxycholecalciferol was measured with a
radioimmunoassay provided by IDS (Boldon, UK). Fol-
lowing an extraction procedure with acetonitrile, the as-
say is carried out with anti-25-OHD ovine antibody, and
phase separation is performed with anti-ovine IgG an-
tiserum. The assay measures 25-OHD3 and 25-OHD2.
Intra-assay and interassay variability are 5% and 8%, re-
spectively. The normal range in our population is 10.0–
60.0 ng/mL.
Serum PTH was measured by means of a commercial
(Nichols Institute Diagnostics, San Juan Capistrano, CA,
USA) immunoradiometric assay, directed to the “intact”
molecule, based on a double-antibody technique. Both
1-84 and “7-84” PTH species are measured together.
Normal range of values is 10 to 65 pg/mL.
Serum osteocalcin, or BGP, was measured by an
immunoradiometric assay (IRMA) (Nichols Institute
Diagnostics). The intra- and interassay variation coeffi-
cients were less than 5.2% and 7.1%, respectively. The
normal range is 6.8 to 32.2 ng/mL.
1,25-dihydroxycholecalciferol was measured (in a sub-
set of 53 patients) with a radioimmunoassay provided by
Nichols Institute Diagnostics. Normal range of values is
19.9 to 67 pg/mL.
ICTP was measured by a radioimmunoassay from
Orion Diagnostica (Oulu, Finland). Normal values in the
general population are within 1.8 and 5 ng/mL serum.
Serum total calcium was determined by a spectropho-
tometric assay using cresolftaleine as substrate. Serum
phosphate and alkaline phosphatase measurements were
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Table 1. Histomorphometric variables
Bone volume (BV/TV) Percent of whole trabecular bone volume occupied by calcified and uncalcified bone tissue
Osteoid volume (OV/BV) Percent of bone volume consisting of osteoid
Osteoid thickness (O.Th.) lm Thickness of osteoid seams
Osteoid surface (OS/BS) Percent of trabecular surface covered by osteoid tissue
Osteoblast surface (Ob.S/BS) Percent of trabecular surface covered by osteoid lined by active osteoblasts
Eroded Surface (ES/BS) Percent of trabecular surface with Howship’s lacunae
Osteoclast surface (Oc.S/BS) Percent of trabecular surface covered by osteoclasts
Osteoclast number (Oc.N/BS) Number of osteoclasts per mm2 of trabecular surface
Single-labeled surface (sLS/BS) The extent of tetracycline single-labeled surface in percentage of trabecular surface
Double-labeled surface (sLS/BS) The extent of tetracycline double-labeled surface in percentage of trabecular surface
Mineralizing surface (MS/BS) The extent of double-labeled plus half the extent of single-labeled surface in percentage of
trabecular surface
Mineralizing surface (MS/OS) The extent of double-labeled plus half the extent of single-labeled surface in percentage of
osteoid surface
Mineral apposition rate (MAR) lm/day The distance between the midpoints of two consecutive labels, divided by the time interval
between the midpoints of the two labelling periods
Bone formation rate (BFR/BS) lm3/lm2/day The volumetric amount of new mineralized bone per unit of trabecular bone surface per day
Adjusted apposition rate (Aj.AR) lm/day The mineral apposition rate corrected for osteoid surface
Mineralization lag time (Mlt) The mean time interval between deposition of osteoid matrix and its mineralization
Osteoid mineralization rate (OMR) The reciprocal value of mineralization lag time
performed spectrophotometrically (DU-65 Beckman;
Beckman Instruments, Fullerton, CA, USA), using
molybdate and p-nitrophenyl-phosphate as respective
substrates. The normal range for the adult population is
2.5 to 4.5 mg/dL and 60 to 170 U/L, respectively.
Bone specimens were fixed using 4% paraformalde-
hyde in 0.1 mol/L phosphate buffer (pH 7.2). They were
then longitudinally halved, dehydrated in acetone, and
embedded without decalcification, in glycol-metacrylate,
as previously described [14]. Sections were cut with a
Reichert-Jung Autocut microtome equipped with a tung-
sten carbide knife. Three to four micrometer thick sec-
tions of the specimens, together with positive controls,
were stained by the aluminum histochemical staining
technique [15]. Alternate sections, 1 to 2 lm thick, were
stained with azure II-methylene blue for histomorpho-
metric measurement of structural and static variables.
Alternate sections, about 5 lm thick, were also prepared
unstained to be examined under ultraviolet light for his-
todynamic evaluation of tetracycline fluorescent labels.
Histomorphometric and histodynamic measurements
were obtained using an interactive color video-based im-
age analysis system (IAS 2000; Delta Sistemi, Rome,
Italy) with a personalized software developed for bone
histomorphometry. The measured variables [16] are re-
ported in Table 1.
Bone volume/tissue volume (BV/TV) was evaluated at
objective magnification of 2.5× and static and dynamic
variables were evaluated at objective magnification of
10× [17]. Normal values (Table 2) for the histomorpho-
metric [17] and histodynamic [14] parameters were ob-
tained in our own histomorphometric laboratory.
Bone pathology was classified as predominant hy-
perparathyroidism, osteomalacia, mixed osteodystrophy,
and adynamic bone disease. The classification was made
on the basis of morphologic criteria, as already reported
[14, 18]. The designation of predominant hyperparathy-
roidism implied a general increase in bone turnover
rate and predominant osteomalacia was characterized
by a decrease in bone turnover rate associated with an
increase of both osteoid surface and thickness. Mixed
osteodystrophy included all the intermediate features be-
tween pure hyperparathyroidism and osteomalacia [19]
and adynamic bone disease was characterized by reduced
bone turnover associated with thin osteoid seams, bone
cell paucity, and a decrease in tetracycline uptake.
Statistical evaluation was carried out with a statisti-
cal package (BMDP statistical software, Cork, Ireland)
on a personal computer. Correlation analysis was made
with the Spearman rank order correlation test and step-
wise multiple regression analysis, while comparison of
groups was evaluated by parametric [analysis of variance
(ANOVA) and Tukey test] and nonparametric (Kruskal-
Wallis and Mann-Whitney) tests. Probability < 0.05 was
considered significant. Values are expressed as mean ±
SD.
RESULTS
Clinical data and the results of laboratory and bone his-
tologic, histomorphometric, and histodynamic evaluation
of all patients, together with normal reference values, are
reported in Table 2. The monthly distribution of blood
sampling for 25-OHD assay and their values are reported
in Figure 1. No circannual pattern of 25-OHD levels was
found. The patients were divided in three groups, accord-
ing to the serum levels of 25-OHD. The subdivision in
groups was made following the indication of population
studies [20, 21]. Therefore the patients were arbitrarily
divided in a first group, with 25-OHD levels between 0
and 15 ng/mL, while patients with 25-OHD levels be-
tween 15 and 30 ng/mL and above 30 ng/mL were in a
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Table 2. Clinical, biochemical, and bone parameters of all patients, with normal values
All Normal values Normal range
Number 104 –
Male/female 61/43 –
Age years 53.4 ± 11.9 –
Hemodialysis length months 96.8 ± 63.4 –
Intact parathyroid hormone pg/mL 555.4 ± 524.2 15–55
25-OHD ng/mL 32.0 ± 18.1 10–40
BGP ng/mL 170.2 ± 151.2 1.4–12.2
Alkaline phosphatase U/L 398.9 ± 432.2 70–170
ICTP ng/mL 148.4 ± 143.5 1.8–5.00
Serum calcium mg/dL 10.47 ± 1.1 8.4–9.5
Serum phosphate mg/day 5.48 ± 1.60 3.5–5.5
Bone volume/tissue volume (BV/TV) % 24.14 ± 7.03 19.01 ± 4.5 9.12–29.13
Osteoid volume/bone volume (OV/BV) % 9.56 ± 8.8 1.39 ± 1.08 0.03–3.25
Osteoid thickness (O.Th,) lm 16.22 ± 6.4 9.55 ± 3.32 5.19–18.68
Osteoid surface/bone surface (OS/BS) % 40.88 ± 21.1 9.58 ± 6.88 0.59–28.03
Osteoblast surface/bone surface (Ob.S/BS) % 17.36 ± 14.1 0.20 ± 0.49 0.00–3.01
Eroded surface/bone surface (ES/BS) % 10.05 ± 5.6 1.52 ± 1.28 0.00–4.97
Osteoclast number/bone surface (Oc.N/BS) no./mm2 1.18 ± 0.9 0.05 ± 0.05 0.00–0.27
Osteoclast surface/bone surface (Oc.S/BS) % 3.49 ± 2.3 0.18 ± 0.19 0.00–0.83
Single-labled surface/bone surface (sLS/BS) % 12.45 ± 10.0 7.16 ± 2.88 4.16–11.38
Double-labeled surface/bone surface (dLS/BS) % 18.59 ± 14.5 6.74 ± 4.26 3.74–14.67
Mineralizing surface/bone surface (MS/BS) % 24.82 ± 16.3 10.35 ± 4.91 6.40–18.11
Mineralizing surface/osteoid surface (MS/OS) % 61.57 ± 28.1 70.83 ± 19.10 62.23–99.15
Mineral apposition rate (MAR) lm/day 1.04 ± 0.5 0.64 ± 0.13 0.45–0.87
Bone formation rate/bone surface (BFR/BS) lm3/lm2 day 0.319 ± 0.3 0.066 ± 0.037 0.029–0.136
Adjusted apposition rate (Aj.AR) lm/day 0.718 ± 0.5 0.441 ± 0.123 0.360–0.648
Mineralization lag time (Mlt) day 119.17 ± 439.4 33.80 ± 10.18 20–46
Osteoid mineralization (OMR) %/day 4.620 ± 2.9 3.23 ± 1.15 2.16–5.01
Abbreviations are: 25-OHD, 25-hydroxyvitamin D; BGP, osteocalcin; ICTP, serum C-terminal cross-linked telopeptide of collagen type 1.
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Fig. 1. Monthly distribution of blood sampling for 25-hydroxyvitamin
D (25-OHD) assay. The lines set the limits of 25-OHD groups.
second group and third group, respectively. Means and
standard deviations of the clinical, biochemical, and his-
tologic, histomorphometric, and histodynamic parame-
ters in the three 25-OHD groups are reported in Table 3,
together with significance levels for parametric and non-
parametric statistical tests.
There was no significant difference between the
25-OHD groups for what concerns average age,
hemodialysis age, serum iPTH, serum calcium, phos-
phate, alkaline phosphatase, and ICTP. The values of
serum 1,25(OH)2D levels (Table 3), pertaining to ap-
proximately one half of the entire case series, did not
show significant difference between the three 25-OHD
groups. Similarly to iPTH, the average value of calcitriol
did not change with increasing 25-OHD serum levels. The
scatter of calcitriol vs. 25-OHD values is represented in
Figure 2.
The aluminum stain was negative in all patients.
The histomorphometric and histodynamic parameters
revealed some interesting and significant differences
between the three groups. In all groups there were
cases of hyperparathyoidism, mixed osteodystrophy, and
low turnover osteodystrophy. The mean values for the
parameters of group 1 were higher than normal for
what concerns osteoid volume/bone volume (OV/BV),
osteoid thickness (O.Th), osteoid surface/bone sur-
face (OS/BS), osteoblast surface/bone surface(Ob.S/BS),
eroded surface/bone surface (ES/BS), osteoclast sur-
face/bone surface (Oc.S/BS), single-labeled surface/bone
surface (sLS/BS), double-labeled surface/bone surface
(dLS/BS), mineralizing surface/bone surface (MS/BS),
and mineralization lag time (Mlt) (Tables 2 and 3). Bone
formation rate/bone surface (BFR/BS) in group 1 was, as
well, on average, elevated, with a mean value at the up-
per limit of normal (mean plus 2 SD). However, the group
with low 25-OHD levels (group 1) showed significantly
lower average values of dLS/BS, MS/BS, and BFR/BS
compared to groups 2 and 3. In addition osteoblast sur-
face/bone surface (Ob.S/BS) and adjusted apposition rate
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Table 3. Clinical, biochemical, and bone parameters of the 25-hydroxyvitamin D (25-OHD) groups with significance of parametric and
nonparametric tests
ANOVA Kruskal-Wallis
25-OHD ng/mL (range) 1 (0–15) 2 (16–30) 3 (>30) P value test P value
Number 15 38 51 – –
Male/female 5/10 23/15 33/18 – –
Age years 57.27 ± 12.0 52.53 ± 11.5 52.92 ± 12.3 NS NS
Hemodialysis length months 102.53 ± 76.6 95.16 ± 62.9 96.52 ± 60.9 NS NS
Intact parathyroid hormone pg/mL 490.71 ± 494.8 670.0 ± 627.2 489.15 ± 436.7 NS NS
25-OHD ng/mL 10.47 ± 1.59 22.03 ± 4.6 45.90 ± 15.7 – –
1,25(OH)2D3 pg/mL 11.07 ± 5.8 (15) 7.86 ± 5.3 (25) 7.26 ± 4.3 (13) NS NS
BGP ng/mL 149.9 ± 181.0 212.48 ± 174.5 145.54 ± 115.9 NS NS
Alkaline phosphatase U/L 348.2 ± 264.9 457.09 ± 532.8 350.47 ± 380.5 NS NS
ICTP ng/mL 108.6 ± 59.18 180.2 ± 186.9 137.06 ± 122.0 NS NS
Serum calcium mg/dL 9.83 ± 1.26 9.97 ± 1.04 10.00 ± 1.1 NS NS
Serum phosphate mg/dL 5.85 ± 1.28 5.7 ± 1.73 5.21 ± 1.5 NS NS
Bone volume/tissue volume (BV/TV) % 21.27 ± 8.00 24.56 ± 6.9 24.56 ± 6.8 NS NS
Osteoid volume/bone volume (OV/BV) % 9.23 ± 13.3 10.41 ± 8.7 9.03 ± 7.3 NS NS
Osteoid thickness (O.Th,) lm 17.60 ± 19.59 17.75 ± 6.8 16.11 ± 6.3 NS NS
Osteoid surface/bone surface (OS/BS) % 38.39 ± 23.8 41.84 ± 21.2 40.87 ± 20.5 NS NS
Osteoblast surface/bone surface (Ob.S/BS) % 11.18 ± 8.3 22.18 ± 16.4 15.57 ± 12.7 0.06 <0.10
Eroded surface/bone surface (ES/BS) % 8.43 ± 6.3 11.20 ± 4.9 9.65 ± 5.7 NS NS
Osteoclast number/bone surface (Oc.N/BS) no./mm2 0.94 ± 0.8 1.41 ± 1.0 1.08 ± 0.8 NS NS
Osteoclast surface/bone surface (Oc.S/BS) % 2.68 ± 2.1 3.90 ± 2.2 3.41 ± 2.3 NS NS
Single-labled surface/bone surface (sLS/BS) % 12.14 ± 9.2 13.69 ± 13.1 11.66 ± 7.7 NS NS
Double-labeled surface/bone surface (dLS/BS) % 9.097 ± 7.4 22.21 ± 13.6 18.67 ± 15.5 <0.03 <0.05a,b
Mineralizing surface/bone surface (MS/BS) % 15.17 ± 8.6 29.06 ± 15.2 24.51 ± 17.6 <0.03 <0.08a,b
Mineralizing surface/osteoid surface (MS/OS) % 42.44 ± 22.4 69.68 ± 26.6 61.17 ± 28.4 NS NS
Mineral apposition rate (MAR) lm/day 0.766 ± 0.40 1.09 ± 0.6 1.08 ± 0.4 NS NS
Bone formation rate/bone surface (BFR/BS) lm3/lm2 day 0.143 ± 0.11 0.373 ± 0.34 0.32 ± 0.4 <0.02a,b <0.09
Adjusted apposition rate (Aj.AR) lm/day 0.392 ± 0.28 0.823 ± 0.53 0.73 ± 0.5 <0.10 NS
Mineralization lag time (Mlt) day 162.31 ± 398.03 93.73 ± 253.93 126.02 ± 546.2 NS NS
Osteoid mineralization (OMR) %/day 3.223 ± 2.41 4.990 ± 3.24 1.37 ± 2.6 NS NS
Hyperparathyroidism/mixed osteodystrophy/low turnover 7/4/4 (2) 27/8/3 (2) 26/17/7 (3) – –
osteodystrophy (adynamic bone disease)
Abbreviations are: ANOVA, analysis of variance; BGP, osteocalcin; ICTP, serum C-terminal cross-linked telopeptide of collagen type 1.
aSignificance of difference group 1 vs. group 2; bSignificance of difference group 1 vs. group 3.
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Fig. 2. Serum calcitriol versus 25-hydroxyvitamin D (25-OHD) in 53
patients.
(Aj.AR) were borderline significantly lower in group 1
compared to the other groups. No statistical difference
between groups 2 and 3 for the biochemical and histo-
logic parameters was observed.
A significant positive correlation was found in the
combined patients of groups 1 and 2 versus serum 25-
OHD for the following parameters: dLS/BS, MS/BS, and
BFR/BS while no significant correlation was found be-
tween these parameters and 25-OHD in the patients of
group 3. The scatters of data, together with graphic rep-
resentation of regression lines, are reported in Figure 3
for the parameter BFR/BS. The results of a stepwise mul-
tiple regression analysis in the patients with 25-OHD lev-
els 0 to 30 and in those with levels >30 are reported in
Table 4. Serum 25-OHD was a significant independent
variable. Correlations of serum 25-OHD levels vs his-
todynamic parameters were significantly positive for the
interval 0 to 30 ng/mL [with the exception of mineralizing
surface/osteoid surface (MS/OS)] and significantly nega-
tive in the group with 25-OHD levels >30 ng/mL. Age,
hemodialysis age, and gender were variables excluded by
the model.
From the scatter of data (Fig. 3), it was evident that
values of the histodynamic parameter at 25-OHD levels
in the order of 30 ng/mL were on average at the same level
of those with higher 25-OHD serum values. In order to
better evaluate the threshold of vitamin D sufficiency, the
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Fig. 3. Bone formation rate/bone surface
(BFR/BS) versus 25-hydroxyvitamin D (25-
OHD) serum levels in groups 1 + 2 and group
3. Regression lines are also reported.
Table 4. Multiple regression analysis, step-wise
Independent variables
PTH 25-OHD
25-OHD, 0 to 30 ng/mL b P b P
Dependent variables
Bone formation rate/bone surface (BFR/BS) 0.000267 <0.001 0.0143 <0.025
Double-labeled surface/bone surface (dLS/BS) 0.0097 <0.003 0.842 <0.002
Adjusted apposition rate (Aj.AR) 0.00051 <0.0001 0.0215 <0.03
Mineralizing surface/bone surface (MS/BS) 0.0117 <0.002 0.782 <0.012
Mineralizing surface/osteoid surface (MS/OS) 0.0268 <0.0001 – –
25-OHD, >30 ng/mL
Bone formation rate/bone surface (BFR/BS) 0.00059 <0.0001 −0.0049 <0.045
Double-labeled surface/bone surface (dLS/BS) 0.0251 <0.0001 −0.232 <0.035
Adjusted apposition rate (Aj.AR) 0.00083 <0.0001 −0.0081 <0.04
Mineralizing surface/bone surface (MS/BS) 0.029 <0.0001 −0.295 <0.02
Mineralizing surface/osteoid surface (MS/OS) 0.0315 <0.001 −0.502 <0.035
patients were divided in narrower 25-OHD intervals, as
shown in Figure 4. The histodynamic parameter BFR/BS
was on average lower, with reduced bone turnover, up to
the 25-OHD level of 20 ng/mL. There was a downslope of
this histodynamic parameter at values of 25-OHD higher
than 40 ng/mL.
In spite of the evidence of a relatively lower bone
turnover due to vitamin D deficiency in the 0 to 20 ng/mL
25-OHD group, there was no increase in the parame-
ters osteoid thickness and osteoid volume/bone volume.
This unexpected finding could be due to the wide range
of PTH serum levels of the patients. The relationship
between serum PTH and the parameter osteoid thick-
ness was investigated as shown in Figure 5. A positive
significant correlation was found between the two pa-
rameters in the patients with 25-OHD values 0 to 20 ng
mL, while the increase of this parameter was not sig-
nificant in the patients with 25-OHD levels higher than
30 ng/mL.
DISCUSSION
The data presented in this study are in favor of a di-
rect role of 25-OHD on bone metabolism, apparently not
mediated through calcitriol, in patients with chronic renal
failure on hemodialysis, affected by renal osteodystrophy,
with a wide range of severity in terms of bone turnover.
The patients with levels of 25-OHD currently defined as
vitamin D deficiency, show on average PTH serum levels
higher than the normal range, nonetheless not higher than
the levels observed in the other 25-OHD groups. Several
factors are at play in promoting hyperparathyroidism in
chronic renal failure, probably masking the effect of vi-
tamin D deficiency. In addition, the levels of circulating
calcitriol do not seem to be influenced by the different
levels of 25-OHD, at least in the range of serum values
of this metabolite spontaneouly observed in our cohort,
as already reported by Ishimura et al [22]. An increase
in calcitriol serum levels has been reported only follow-
ing administration of pharmacologic doses of 25-OHD
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[23]. Therefore, our results favor the conclusion that, in-
dependently of serum PTH and calcitriol serum levels,
25-OHD holds a direct and autonomous influence on the
process of bone formation and mineralization. Very low
levels of 25-OHD in chronic renal failure seem to be com-
patible with increased bone turnover, presumably mainly
PTH-dependent, with an increase of several parameters
which are an expression of bone formation and resorp-
tion. However, serum values of 25-OHD lower than 20
ng/mL appear to moderate the extent of bone formation
rate and the velocity of osteoid synthesis and mineral-
ization, which would be allowed by higher levels of the
vitamin D metabolite. As shown by other reports [9], one
would expect, with low levels of 25-OHD, an increase in
the evidence of osteomalacia, histologically characterized
by an increase of the parameters osteoid volume/bone
volume and osteoid thickness. However, our finding is
the average result of patients of the experimental groups
with a wide range of values of iPTH serum levels. With
correlation analysis, a progressive increase in the param-
eter osteoid thickness was observed with increasing PTH
serum levels in the low 25-OHD group, while this posi-
tive correlation was not observed at 25-OHD levels >30
ng/mL. This finding indicates that the increase in histo-
logic evidence of a mineralization defect can be better
detected with increased rate of osteoid synthesis induced
by elevated PTH serum levels, ending up in the in-
crease of the parameter osteoid thickness. The study of
Ghazali et al [9] confirms that the finding of osteomalacia
is found in those cases of low serum 25-OHD levels when
combined with elevated PTH levels, while decreased 25-
OHD associated to relatively low PTH serum levels was
not associated to radiologic evidence of osteomalacia.
Despite the relatively reduced bone formation rate, de-
ficiency of 25-OHD could not be recognized as a cause
of adynamic bone disease, since cases of adynamic bone
disease can be found in all three groups of 25-OHD levels.
Despite the absence of a significant difference in aver-
age histodynamic values between groups 2 and 3, some
more information derives from the multiple regression
analysis. Due to the relatively small number of cases
in group 1, they were combined to cases of group 2.
25-OHD showed an independent significant positive cor-
relation with several histomorphometric and histody-
namic parmeters in the range 0 to 30 ng/mL. A negative
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correlation was found for the same parameters as depen-
dent variables in the patients of group 3. This finding is
in favor of a dependence from 25-OHD of bone turnover
in the 25-OHD serum level range, including vitamin D
deficiency and insufficiency (0 to 15 and 15 to 30 ng/mL,
respectively). However, from further subdivision of the
patients, a real defect in 25-OHD can be identified in
cases with a 25-OHD levels below 20 ng/mL. In addi-
tion, an optimal 25-OHD serum level can be identified at
around 30 ng/mL, since with higher levels of the vitamin
D metabolite the total vitamin effect seems to be exces-
sive, since these levels were accompanied by a decrease
in the parameters of bone turnover.
A direct effect of 25-OHD on bone cells should be en-
visaged as an action mediated by the vitamin D receptor,
where calcitriol normally acts with an elevated affinity.
Relatively recent studies in vitro, using transcriptional ac-
tivation techniques, have shown that 25-OHD is only 500
times less active than calcitriol [22]. Therefore, when cal-
citriol serum levels are in the low range, concentration of
serum 25-OHD >30 ng/mL should be sufficiently high to
act on the vitamin D receptors in the place of calcitriol,
at least for what concerns osteoblastic stimulation and
maturation. Therefore, It is likely that in chronic renal
failure with low levels of calcitriol, 25-OHD contributes
a significant part of the total vitamin D effect. However,
an extrarenal peripheral production of calcitriol not de-
tected by increased serum levels cannot be entirely ruled
out [25]. As for the decrease of bone histomorphometric
parameters for 25-OHD levels above 40 ng/mL, a direct
vitamin D effect on bone of 25-OHD or through an in-
crease in the synthesis of 24,25(OH)2D3 levels [26, 27]
can be hypothesized.
On a practical ground, in chronic renal failure, with
special regard to hemodialysis and peritoneal dialysis pa-
tients, evaluation of 25-OHD serum levels is necessary,
and in case of values lower than 30 ng/mL, vitamin D
should be administered as cholecalciferol or as 25-OHD
[28], at doses which should avoid excessive increases of
25-OHD serum levels.
This study shows some limitations due to the fact of
being a cross-sectional retrospective study. A prospec-
tive study with administration of vitamin D, correction
of serum levels of 25-OHD and reassessment of bone
histology would have been a more comprehensive pro-
tocol. Nevertheless, this is the only study with a rela-
tively large histology based data relating 25-OHD levels
to bone histomorphometry and histodynamic evaluation
in hemodialysis chronic renal failure.
CONCLUSION
25-OHD levels below 20 ng/mL are accompanied by
relatively lower bone turnover. The optimal level of 25-
OHD appears to be 20 to 40 ng/mL, while levels of the
vitamin D metabolite higher than 40 ng/mL are probably
associated to excessive vitamin D effect. In addition the
current findings support the recent recommendations by
National Kidney Foundation Dialysis Outcomes Quality
Initiative (KDOQI) [28] on the assessment of 25-OHD
serum levels in patients with chronic kidney disease.
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